Aktienanalyse zu Procept Biorobotics Corp (PRCT)PRCTProcept Biorobotics Corp

PROCEPT BioRobotics Corporation is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). It designed Aquablation therapy to deliver outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH that is independent of prostate size and shape and delivers resection independent of surgeon experience. It manufactures the robotic systems, the single-use disposable handpiece, integrated scope and other accessories at its facility in San Jose, California. Each robotic system is shipped to its customers with a third-party manufactured ultrasound system and probe. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Procept Biorobotics Corp is currently not a strong buy. The stock is trading at $20.83, which is significantly below its 200-day simple moving average of $26.22, indicating a bearish trend. The RSI is at 46.01, suggesting the stock is neither overbought nor oversold, but the negative sentiment from recent downgrades and ongoing class action lawsuits poses a risk. The company reported a gross margin of 66.01% in Q2 2026, which is strong, but the net loss of $26.86 million in the same quarter raises concerns about profitability. The main risk is the ongoing class action lawsuits related to sales practices, which could further impact investor confidence and stock price.